MTI-31

CAS No. 1567915-38-1

MTI-31( LXI-15029 | mTOR inhibitor-31 )

Catalog No. M12239 CAS No. 1567915-38-1

MTI-31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 560 Get Quote
10MG 878 Get Quote
25MG 1305 Get Quote
50MG 1764 Get Quote
100MG 2367 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    MTI-31
  • Note
    Research use only, not for human use.
  • Brief Description
    MTI-31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR).
  • Description
    MTI-31 (LXI-15029, mTOR inhibitor-31) is a novel potent, selective mTORC1/mTORC2 inhibitor with Kd of 0.2 nM (mTOR), displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G; showed an IC50 value 39 nM in LANCE? assay of mTOR substrate phosphorylation; dose-dependently inhibits of both the mTORC1 substrates P-S6K1(T389), P-S6(S235/6), P-4EBP1(T70) and mTORC2 substrate P-AKT(S473) tumor cell lines harboring mTOR pathway dysregulation with IC50 of <0.12 uM; potently inhibited cell proliferation (IC50 <1 mmol/L) and in vivo tumor growth in multiple NSCLC models of EGFR/T790M, EML4-ALK, c-Met or KRAS (MED <10 mg/kg), also suppressed programmed death ligand 1 (PD-L1) in EGFR- and ALK-driven NSCLC, mediated in part by mTORC2/AKT/GSK3β-dependent proteasomal degradation.
  • In Vitro
    MTI-31 acts as a potent and selective inhibitor of mTOR enzymatic activity capable of targeting both mTORC1 and mTORC2 functions in cancer cells.MTI-31 (0.01-100 μM) elicits a potent and more substantial inhibition of cell growth than that of Rapamycin.Treatment with MTI-31 for 6 h demonstrates a dose-dependent inhibition of both the mTORC1 substrates P-S6K1(T389), P-S6(S235/6), P-4EBP1(T70) and mTORC2 substrate P-AKT(S473), achieving 50% inhibition at ≤0.12 μM in three representative tumor cell lines harboring mTOR pathway dysregulation (786-O renal, U87MG glioma and MDA-MB-453 breast).MTI-31-induced apoptosis requires mTORC2-regulated Bim- and GSK3 activity. Cell Proliferation Assay Cell Line:MDA-MB-453 cells Concentration:0.01, 0.1, 1, 10, 100 μM Incubation Time:3 days Result:Significantly inhibited cellular proliferation after treatment for 3 days.Western Blot Analysis Cell Line:786-O renal, U87MG glioma and MDA-MB-453 breast cells Concentration:0.12, 0.37, 1.11, 3.33, 10 μM Incubation Time:6 hours Result:Demonstrated a dose-dependent inhibition of both the mTORC1 substrates P-S6K1(T389), P-S6(S235/6), P-4EBP1(T70) and mTORC2 substrate P-AKT(S473).
  • In Vivo
    MTI-31 is a potent mTOR inhibitor in vivo and elicits strong antitumor efficacy. MTI-31(5-40 mg/kg; orally) is efficacious in several tumor models harboring HER2+/PIK3CAmut and/or PTEN-deficiency exemplified by MDA-MB-453 and 786-O. Treatment of tumor bearing nude mice with orally administered MTI-31 inhibits growth of H1975 tumors (25 mg/kg/d; orally) or U87MG tumors (30 mg/kg/d; orally). Animal Model:Female nude mice bearing tumors of MDA-MB-453, 786-O or HCC1806 Dosage:2.5, 5, 10, 20, 40 mg/kg for MDA-MB-453 and 786-O; 20 and 40 mg/kg for HCC1806 Administration:Treated orally via a once daily (qd) regimen Result:Was efficacious in several tumor models harboring HER2+/PIK3CAmut and/or PTEN-deficiency exemplified by MDA-MB-453 and 786-O. Demonstrated a dose proportional tumor growth inhibition (TGI) with a minimum efficacious dose (MED) of 5 mg/kg (>50% TGI, p<0.01) and a maximum tolerated dose (MTD) of 40 mg/kg (7-15% body weight loss without mortality).
  • Synonyms
    LXI-15029 | mTOR inhibitor-31
  • Pathway
    PI3K/Akt/mTOR signaling
  • Target
    mTOR
  • Recptor
    mTOR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1567915-38-1
  • Formula Weight
    474.565
  • Molecular Formula
    C26H30N6O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 8.33 mg/mL (17.55 mM)
  • SMILES
    ——
  • Chemical Name
    3-(4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-2-((S)-3-methylmorpholino)pyrido[2,3-d]pyrimidin-7-yl)-N-methylbenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Qian J, et al. Oncotarget. 2016 Oct 11;7(41):67071-67086. 2. Zhang Q, et al. Clin Cancer Res. 2019 Feb 22. pii: clincanres.2548.2018.
molnova catalog
related products
  • ML239

    ML239 is a potent and selective inhibitor of breast cancer stem cells, with an IC50 of 1.16 μM.

  • mTOR-IN-1

    A potent and selective mTOR inhibitor with Ki of 1.5 nM.

  • NV-5138

    NV-5138 is a selective and orally active activator of brain mTORC1, with antidepressant effects.